Approval Was the First Hurdle, Not the Last
Revolution Medicines, Inc. (NASDAQ:RVMD) is no longer valuing a theoretical pancreatic cancer drug. Rasonque (daraxonrasib), approved by the FDA in August, is available to U.S. patients, and a European Medicines Agency committee recommended authorization on October 15. The investment debate has therefore shifted from whether the treatment works to whether commercial uptake can grow fast enough to justify a roughly $38.14 billion equity valuation.
The once-daily oral drug treats specified adults with metastatic pancreatic cancer following prior therapy or when combination chemotherapy is unsuitable. In the pivotal RASolute 302 study, patients on daraxonrasib achieved median overall survival of 13.2 months versus 6.7 months with chemotherapy. That is substantial clinical evidence, though clinical success and profitable sales are different thresholds.
Revolution Medicines, Inc. ranks second in 11 Best Cancer Stocks to Invest In Now, based on 105 hedge fund holders in Q2 2026. Which established drugmaker topped the list, and why did a newly commercial-stage biotech attract almost as much institutional interest?
Global Expansion Increases Both Reach and Cost
Reuters reported on October 15 that Revolution Medicines, Inc. is preparing to market Rasonque directly in Europe rather than depend on a regional licensing partner. The EMA committee’s recommendation is not final authorization: the European Commission still needs to decide, and individual health systems will negotiate reimbursement and prices. Commercial control could preserve a larger share of future revenue, but also requires sales teams, market access operations, and upfront spending.
The U.S. wholesale price is $39,800 for a 30-day supply, before rebates, discounts or financial assistance. Annualizing the list price would exaggerate realized revenue because treatment duration, payer coverage, net pricing, and eligibility all vary. Our examination of Rasonque’s launch price and patient-access barriers explains why commercial forecasts cannot simply multiply that sticker price by the addressable patient population.
Analysts cited by Reuters estimate possible peak global Rasonque sales of $11.5 billion, while Stifel sees $3.2 billion–$3.3 billion of peak sales outside the United States. These are long-run expectations, not current revenue or company guidance. The valuation depends on penetration, treatment persistence, and actual reimbursement, especially in countries where national systems negotiate aggressively.
A Strong Funding Buffer Still Carries a Price
The financing position helps Revolution Medicines, Inc. pursue that strategy. At June 30, the company reported approximately $3.94 billion in cash, cash equivalents, and marketable securities. The company has also established financing arrangements with Royalty Pharma totaling up to $2 billion. As of its second-quarter update, approximately $1.5 billion remained available under those arrangements, subject to specified milestones. This supports commercialization plans but does not make the entire commitment equivalent to unrestricted cash already on the balance sheet. That capital reduces near-term funding pressure, but royalties, financing costs, and potential shareholder dilution still matter to the return shareholders eventually receive.
In Q2, research and development expense reached $394.9 million, up from $224.1 million a year earlier, while general and administrative expense rose to $110.2 million from $40.6 million. With no product revenue before the late-August approval, the company was spending to build both a pipeline and its first commercial organization. Even a successful launch must ultimately absorb that operating base.
The Seeking Alpha data as of October 19 shows no meaningful trailing or forward P/E for Revolution Medicines, Inc. because the business remains loss-making. Instead, it values the stock at about $38.14 billion, against $3.94 billion in cash and approximately $1.19 billion of total debt. A projected P/E of 32.39 times for 2029 depends on analysts’ future profitability estimates materializing. Conventional near-term earnings comparisons with mature pharmaceutical companies are therefore misleading.
A Launch Test Investors Can Actually Measure
Wall Street generally sees commercial potential but not unanimity about its value. Truist reiterated Buy on Revolution Medicines, Inc. and raised its target to $241 from $240 on October 19; RBC Capital retained Outperform with a $260 target on October 14. Those targets embed differing assumptions about launch speed, follow-on indications, and treatment competition. One additional development is the combination opportunity: Tango Therapeutics’ work pairing vopimetostat with daraxonrasib shows how the RAS treatment could expand beyond its initial use, although early combination data cannot establish a commercial market.
Insider Monkey tracked 105 hedge funds holding the stock in Q2, down from 106 in Q1. Short interest rose to 11.93 million shares at September 30 from 9.73 million in August, equivalent to 5.88% of float. These historical positions predate the European recommendation and do not reveal investors’ current views.
The decisive metrics now are net U.S. prescriptions, treatment duration, payer access, and costs of launching abroad. Rasonque has made the medical case. Shareholders still need evidence that commercial profits can support a valuation built on years of anticipated success.
READ NEXT: Merck’s Rally Reflects Renewed Confidence, but Has the Market Priced in Too Much? and Tango Therapeutics (TNGX) Could Benefit From Pancreatic Ductal Adenocarcinoma Data Announcement
Hedge Fund Resource Center